Literature DB >> 19796185

Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients.

D R Carvalho1, M M M Navarro, B J A F Martins, K E F A Coelho, W D Mello, R I Takata, C E Speck-Martins.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a severe genetic disorder reported worldwide. A specific heterozygous mutation (c.617G> A; p.R206H) in the activin A type I receptor gene (ACVR1) is regarded as the genetic cause of FOP in all classically affected individuals worldwide. However, a few patients with FOP variants harbor distinct mutations in ACVR1. We screened a group of FOP Brazilian population for mutations in ACVR1. Of 16 patients with a classic FOP phenotype (10 males and 6 females, age range of 3-42 years), all had the classic mutation (p.R206H). One 21-year-old woman with a variant FOP phenotype had the previously reported c.983G> A mutation (p.G328E). Our study contributes to the understanding of the predominant FOP phenotype and genotype and suggests that variant FOP phenotypes are associated with specific mutations in ACVR1 gene.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19796185     DOI: 10.1111/j.1399-0004.2009.01256.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  12 in total

1.  A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.

Authors:  Celia L Gregson; Peter Hollingworth; Martin Williams; Kirsten A Petrie; Alex N Bullock; Matthew A Brown; Jon H Tobias; James T Triffitt
Journal:  Bone       Date:  2010-10-29       Impact factor: 4.398

2.  Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.

Authors:  Bettina E Mucha; Megumi Hashiguchi; Joseph Zinski; Eileen M Shore; Mary C Mullins
Journal:  Bone       Date:  2018-01-04       Impact factor: 4.398

3.  The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases.

Authors:  Wei Zhang; Keqin Zhang; Lige Song; Jing Pang; Hongxing Ma; Eileen M Shore; Frederick S Kaplan; Peijun Wang
Journal:  Bone       Date:  2013-09-17       Impact factor: 4.398

Review 4.  Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation.

Authors:  Irina Hüning; Gabriele Gillessen-Kaesbach
Journal:  Mol Syndromol       Date:  2014-08-07

5.  Clinical and molecular characterisation of two siblings with fibrodysplasia ossificans progressiva, from the Colombian Pacific coast (South America).

Authors:  Harry Pachajoa; Andres Felipe Ramirez Botero
Journal:  BMJ Case Rep       Date:  2015-06-08

Review 6.  Cellular and morphological aspects of fibrodysplasia ossificans progressiva. Lessons of formation, repair, and bone bioengineering.

Authors:  Anderson Martelli; Arnaldo Rodrigues Santos
Journal:  Organogenesis       Date:  2014-10-31       Impact factor: 2.500

Review 7.  TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation.

Authors:  Md Shaifur Rahman; Naznin Akhtar; Hossen Mohammad Jamil; Rajat Suvra Banik; Sikder M Asaduzzaman
Journal:  Bone Res       Date:  2015-04-14       Impact factor: 13.567

Review 8.  The biological function of type I receptors of bone morphogenetic protein in bone.

Authors:  Shuxian Lin; Kathy K H Svoboda; Jian Q Feng; Xinquan Jiang
Journal:  Bone Res       Date:  2016-04-05       Impact factor: 13.567

9.  From mysteries to medicines: drug development for fibrodysplasia ossificans progressive.

Authors:  Frederick S Kaplan; Robert J Pignolo; Eileen M Shore
Journal:  Expert Opin Orphan Drugs       Date:  2013-08       Impact factor: 0.694

Review 10.  Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis.

Authors:  Frederick S Kaplan; Salin A Chakkalakal; Eileen M Shore
Journal:  Dis Model Mech       Date:  2012-11       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.